Mark Smith, Finch Therapeutics CEO
FDA slaps hold on Finch's microbiome C. difficile treatment, as biotech blames Covid-19 and old manufacturer
Drugmakers working on treatments for C. difficile infections are having a bad week.
Just one day after Pfizer reported its C. difficile vaccine candidate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.